Clinical Significance of Factor V Levels in Thrombotic Risk Assessment and Bleeding Disorders

Factor V Deficiency and Bleeding Risk

The American College of Medical Genetics recommends factor V Leiden testing for thrombotic risk assessment, as it accounts for 90-95% of APC resistance cases 1
The lifetime thrombosis risk for factor V Leiden heterozygotes is approximately 10%, while homozygotes exceed 80% 2

The American College of Medical Genetics suggests that testing for factor V Leiden should be considered in patients with venous thromboembolism, particularly those with early-onset events, unusual thrombosis sites, recurrent thrombosis, or family history 1, 4
The National Society of Genetics Counselors recommends that when ordering factor V Leiden testing, simultaneously consider testing for prothrombin 20210A mutation and plasma homocysteine levels, as venous thrombosis is multifactorial and multiple genetic risk factors commonly coexist 1, 4

The American Society of Regional Anesthesia and Pain Medicine recommends that for patients with factor V deficiency requiring neuraxial anesthesia, maintain factor V levels ≥50 IU/dL during the procedure and while epidural catheters remain in situ 5
The International Society on Thrombosis and Haemostasis suggests that individualized risk assessment must account for bleeding history severity, not just laboratory values 5

The American Academy of Pediatrics recommends that in suspected child abuse cases with intracranial hemorrhage, recognize that factor V deficiency is extraordinarily rare and should not be invoked without compelling laboratory evidence 6